# Jong-Seok Lee

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/jong-seok-lee/

## Facts

| Field | Value |
| --- | --- |
| Citations | 17,682 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 31 |
| i10-index | 51 |
| Last Known Institution | Korea Advanced Institute of Science and Technology |
| OpenAlex ID | https://openalex.org/A5100668168 |
| ORCID iD | https://orcid.org/0000-0003-3733-3573 |
| Works | 135 |

## Researcher papers

- [Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer](https://scholariq.org/papers/pembrolizumab-for-the-treatment-of-non-small-cell-lung-cancer/)
- [Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial](https://scholariq.org/papers/atezolizumab-versus-docetaxel-in-patients-with-previously-treated-non-small-cell/)
- [Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial](https://scholariq.org/papers/durvalumab-with-or-without-tremelimumab-plus-platinum-etoposide-versus-platinum/)
- [Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study](https://scholariq.org/papers/durvalumab-as-third-line-or-later-treatment-for-advanced-non-small-cell-lung/)
- [First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial](https://scholariq.org/papers/first-line-nivolumab-plus-ipilimumab-in-advanced-nsclc-4-year-outcomes-from-the/)
- [Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non–Small-Cell Lung Cancer Harboring <i>ROS1</i> Rearrangement](https://scholariq.org/papers/open-label-multicenter-phase-ii-study-of-ceritinib-in-patients-with-non-small/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)

## Researcher university

- [Korea Advanced Institute of Science and Technology](https://scholariq.org/institutions/korea-advanced-institute-of-science-and-technology/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.